

Press Release

febit establishes US company

- **febit Inc. launches the innovative GENIOM biochip system in the US**
- **GENIOM sets out to penetrate the largest biochip market worldwide**
- **Supporting febit Inc., SAP co-founder Hopp expands its investment in the US biotech market**

Heidelberg / Medford (USA), August 14, 2006. Today, febit biotech gmbh announced the establishment of febit Incorporation, a Delaware Company based in Medford, Boston/USA. febit Inc. will be supporting all operations throughout America: in the US, Canada and the Southern American countries. With its presence in the Unites States, febit enters the largest market for biochip technology worldwide.

Thus, GENIOM sales and customer support will be handled by highly qualified stuff on site. All team members are experienced in the US market. The knowledge transfer required for a successful start of febit Inc. was achieved by several months of prior training for technical specialists and the US management. Temporary delegation of febit biotech gmbh staff is envisaged as well. A fully equipped application laboratory is already established that will enable customers to perform hands-on tests of their applications on the GENIOM system and develop novel assays in cooperation with febit Inc.. In addition, febit will offer workshops featuring various GENIOM applications. Production for the Americas (Northern and Southern America) is expected to take place in close cooperation with US-based companies.

febit Inc. is directed by Claus E. Schmidt, Vice President Operations & General Manager, a successful entrepreneur experienced in knowledge transfer between Europe and the USA. In addition, he contributes valuable expertise in the field of chemical engineering. febit Inc. CEO Cord F. Stähler successfully directs febit biotech gmbh in Heidelberg as well and is an accomplished manager in the international biomedical technology business. The Operative Management is completed by Stefan M. Matysiak, PhD, Director Customer Care, who is primarily responsible for customer care and the applications laboratory. He has several years of experience in research and development, working for renowned companies and institutions in the US and Germany, such as Applied Biosystems Inc. and the German Cancer Research Center.

The Supervisory Board of febit Inc. – as the one of febit biotech gmbh – is chaired by Dr. Gerald Möller, Director of HBM BioCapital Management GmbH and former president and CEO of the Boehringer Mannheim Group. Vice Chairman of the Supervisory Board is Michael Kranich, Director of DH-Capital GmbH & Co. KG and OH-Beteiligungen GmbH & Co. KG that holds the majority of febit biotech GmbH for the Hopp family. Dietmar Hopp, co-founder of SAP and its CEO and Chairman for many years, is the most potent single investor of the German biotech industry. He primarily invests in young, promising companies in that business such as febit biotech gmbh. Supporting febit's establishment on the American continent, he expands his engagement in the fastest-growing biotech market.

Establishing a US-based company is a logical step for Cord F. Stähler, CEO of febit Inc.: „After a successful start of GENIOM in the European market, penetration of the US as the largest biochip market is an essential move in our marketing strategy. We are confident that our US customers as well will be convinced by the unique speed and flexibility of our system in microarray synthesis and analysis. With a highly efficient team in the country, we are able to specifically address this market and successfully expand our business there.“

Based in Medford, Massachusetts, febit Inc. will take advantage of the high density of research institutions, biotech firms and pharmaceutical companies in the Boston metropolitan area. Renowned institutions in the region include the Massachusetts Institute of Technology (MIT), Harvard University, Tufts University, Wentworth Institute of Technology and the Novartis Institutes for Biomedical Research.

For more information please visit febit Inc. online at www.febit.com.

Background information

With the DNA analysis device GENIOM, febit provides the user with a whole new world of experimental opportunities: it enables the design, synthesis, application and analysis of user-specified biochips in his own laboratory. In a fully integrated benchtop device, GENIOM offers unparalleled speed and flexibility plus complete privacy of sensitive research data.

Within a single day, DNA sequence information is translated into microarray experiments – and results. These features render GENIOM a unique system on the worldwide market. Currently, GENIOM is used primarily for basic research in molecular biology and medicine.



febit Inc., Medford (USA)

febit Inc.

Claus E. Schmidt
200 Boston Avenue, Suite 1850
Medford, MA 02155
USA
Phone: +1 781 391-4360
Fax: +1 781 391-4362
info@febit.com
www.febit.com
www.geniom.com

febit biotech gmbh

Cord F. Stähler
Im Neuenheimer Feld 519
69120 Heidelberg
Germany
Phone: +49 (0) 6221 6510-300
Fax: +49 (0) 6221 6510-329
E-Mail: info@febit.de
www.febit.de
www.geniom.de